Compare Icl Group Ltd (ICL) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Viatris Inc — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 3.1× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Viatris Inc for 57 Days on average.
| ICL | VTRS | |
|---|---|---|
Market Cap | $6.47B | $20.03B |
Volume | 1,387,140 | 14,109,977 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $18.27 |
52-Week Low | $4.80 | $9.74 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $9.11B | $32.15B |
Dividend Yield | 4.11% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL Group trades at $5.015, down 1.28% today, with a bearish technical outlook despite recent earnings beats. The company maintains stable cash flow generation with $1.06B from operations in 2025, though revenue has declined from $10.0B in 2022 to $7.15B in 2025. Recent Q2 2026 results showed earnings of $0.12 per share, beating estimates, and the company announced a dividend of $0.06 payable September 16, 2026.
While ICL shows fundamental stability with reasonable valuation metrics (P/E 20.83, P/S 0.84), the stock faces headwinds from declining profitability margins and bearish technical signals. Analyst consensus remains neutral with 100% hold ratings, though the $6.08 price target suggests 21% upside potential from current levels.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
